NGF (Nerve Growth Factor)
Nerve Growth Factor (NGF) is a neurotrophic protein essential for the survival, maintenance, and differentiation of sympathetic and sensory neurons. It signals through TrkA and p75NTR receptors and is a major research target in Alzheimer's disease, chronic pain, and corneal nerve regeneration.
Nerve Growth Factor (NGF) is a 13.5 kDa homodimeric neurotrophic protein first discovered by Rita Levi-Montalcini and Stanley Cohen in the 1950s, earning them the 1986 Nobel Prize. NGF plays a critical role in the development, maintenance, and survival of sympathetic and sensory neurons throughout life.
Overview
NGF was the first neurotrophin identified and remains the best characterized member of the neurotrophin family, which also includes BDNF, NT-3, and NT-4/5. In the peripheral nervous system, NGF is the primary survival factor for sympathetic neurons and nociceptive sensory neurons of the dorsal root ganglia. In the central nervous system, NGF is the principal trophic factor for basal forebrain cholinergic neurons (BFCNs) that project to the hippocampus and cortex -- populations that degenerate early in Alzheimer's disease.
The dual-receptor system creates a signaling dichotomy: TrkA activation promotes survival, differentiation, and synaptic strengthening, while p75NTR can signal either pro-survival (when co-expressed with TrkA) or pro-apoptotic pathways (when expressed alone). This receptor balance is central to understanding NGF's roles in both neuroprotection and pain sensitization (Reichardt, 2006).
Mechanism of Action
NGF exerts its biological effects through two structurally distinct receptors with different affinities and downstream signaling cascades:
TrkA receptor (NTRK1): NGF binds TrkA with high affinity (Kd ~10⁻¹¹ M), inducing receptor dimerization and autophosphorylation at tyrosine residues Y490, Y674/675, and Y785. This activates three major cascades:
- Ras/MAPK/ERK pathway: Phospho-Y490 recruits Shc/FRS2, activating Ras-Raf-MEK-ERK signaling that drives neuronal differentiation and neurite outgrowth (Kaplan & Miller, 2000)
- PI3K/Akt pathway: Recruitment of PI3K via Gab1/IRS leads to Akt phosphorylation, promoting cell survival by inhibiting pro-apoptotic factors Bad and caspase-9
- PLCgamma/PKC pathway: Phospho-Y785 activates PLCgamma, generating IP3 and DAG, leading to calcium release and PKC activation involved in synaptic plasticity
p75NTR receptor: NGF binds p75NTR with lower affinity (Kd ~10⁻⁹ M). Signaling outcomes depend on receptor context:
- With TrkA co-expression: p75NTR enhances TrkA affinity for NGF and promotes survival via NF-kappaB activation (Hempstead, 2002)
- Without TrkA: p75NTR activates JNK and ceramide pathways, promoting apoptosis. ProNGF binds p75NTR/sortilin complex with high affinity, preferentially triggering cell death (Nykjaer et al., 2004)
Pain signaling: NGF-TrkA signaling in nociceptive neurons upregulates TRPV1 (via p38 MAPK phosphorylation), substance P, and CGRP, directly lowering pain thresholds. NGF also sensitizes sodium channels Nav1.8 and Nav1.9, contributing to peripheral sensitization (Pezet & McMahon, 2006).
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Corneal Nerve Regeneration
The cornea is the most densely innervated tissue in the body, primarily by TrkA-expressing sensory nerves. Corneal nerve damage from surgery (LASIK, keratoplasty), infection (herpes simplex keratitis), or diabetes leads to neurotrophic keratopathy (NK) -- a degenerative condition causing impaired healing and corneal ulceration.
Recombinant human NGF (rhNGF, cenegermin, brand name Oxervate) was approved by the EMA (2017) and FDA (2018) for neurotrophic keratitis -- making it the first approved NGF-based therapeutic. In the REPARO Phase II trial, topical rhNGF (20 microg/mL, 6 drops/day for 8 weeks) achieved corneal healing in 74.5% of patients with moderate-to-severe NK compared to 43.1% for vehicle (Bonini et al., 2018). Nerve regeneration was confirmed by in vivo confocal microscopy.
Peripheral Neuropathy
NGF deficiency contributes to diabetic peripheral neuropathy. Phase II trials of rhNGF in diabetic neuropathy showed improvements in sensory nerve function but were limited by injection site hyperalgesia -- a predictable on-target effect of TrkA activation in nociceptors (Apfel et al., 2000). This dose-limiting side effect has driven research toward selective TrkA agonists that preserve neurotrophic effects while minimizing pain sensitization.
Neuropsychiatric Applications
Reduced NGF levels have been documented in major depressive disorder, post-traumatic stress disorder, and schizophrenia. In animal models, intranasal NGF administration improves depressive-like behavior and hippocampal neurogenesis. NGF also modulates hypothalamic-pituitary-adrenal (HPA) axis activity, suggesting a role in stress response regulation (Alleva & Branchi, 2006).
Alzheimer's Disease and Cholinergic Neurons
The cholinergic hypothesis of Alzheimer's disease places NGF at the center of therapeutic strategy. Basal forebrain cholinergic neurons (BFCNs) depend on retrograde NGF transport from hippocampal and cortical targets for survival. In AD, failed retrograde transport -- not NGF production itself -- leads to BFCN degeneration (Mufson et al., 2008).
Mark Tuszynski's group at UCSD pioneered direct NGF gene therapy to BFCNs. In a Phase I trial, ex vivo NGF gene delivery via autologous fibroblasts implanted into the nucleus basalis of Meynert showed trophic effects on cholinergic neurons at autopsy and suggested cognitive stabilization in 8 patients over 22 months (Tuszynski et al., 2005). A subsequent Phase II trial using AAV2-NGF (CERE-110) delivered stereotactically to the nucleus basalis enrolled 49 patients but did not meet its primary endpoint of cognitive improvement at 2 years, though post-hoc analysis revealed that optimal targeting correlated with cholinergic neuron response (Rafii et al., 2014; Castle et al., 2020).
Pain Signaling and Anti-NGF Therapeutics
NGF is a potent algogenic mediator. Injection of NGF into human volunteers produces sustained hyperalgesia lasting days to weeks. Elevated NGF levels are found in synovial fluid of osteoarthritis patients and in chronic pain conditions including interstitial cystitis and chronic pancreatitis (Denk et al., 2017).
Anti-NGF monoclonal antibodies represent a major therapeutic class:
- Tanezumab (Pfizer/Lilly): Humanized IgG2 anti-NGF antibody. Phase III trials in osteoarthritis demonstrated significant pain reduction (WOMAC pain scores) compared to placebo and comparable efficacy to NSAIDs. FDA issued a Complete Response Letter in 2021 due to concerns about rapidly progressive osteoarthritis (RPOA) in a subset of patients (Schnitzer et al., 2019)
- Fasinumab (Regeneron/Teva): Fully human IgG4 anti-NGF antibody. Phase II/III trials showed analgesic efficacy in osteoarthritis and chronic low back pain, with similar joint safety concerns (Dakin et al., 2019)
The RPOA signal has prompted investigation into dose-dependent effects and patient selection criteria. The FDA Advisory Committee voted 19-1 in favor of tanezumab approval in 2021 with risk management, though final approval has not been granted.
Safety Profile
NGF's safety profile is complex due to its dual role as a neurotrophic and nociceptive mediator. Topical cenegermin (Oxervate) has a well-characterized safety profile with common adverse effects limited to eye pain (16%), corneal deposits, and foreign body sensation. Systemic rhNGF administration causes dose-limiting injection site hyperalgesia and myalgia mediated by TrkA activation on nociceptors -- the primary reason subcutaneous NGF trials for diabetic neuropathy were discontinued (Apfel et al., 2000).
Anti-NGF antibodies (tanezumab, fasinumab) carry a risk of rapidly progressive osteoarthritis (RPOA), particularly at higher doses and when combined with NSAIDs. The mechanism likely involves reduced proprioceptive pain signaling allowing continued joint damage. Peripheral neuropathy has also been reported with anti-NGF antibodies, attributed to inhibition of NGF-dependent sensory neuron maintenance.
Intracerebroventricular NGF delivery in early clinical trials caused back pain and weight loss, attributed to NGF effects on hypothalamic neurons. Gene therapy approaches using AAV2-NGF (CERE-110) showed acceptable safety profiles over follow-up periods exceeding 2 years.
Pharmacokinetic Profile
NGF (Nerve Growth Factor) — Pharmacokinetic Curve
Intracerebroventricular, intranasal, topical (eye drops), gene therapyQuick Start
- Route
- Intracerebroventricular, intranasal, topical (eye drops), gene therapy
Molecular Structure
- Formula
- C583H908N162O177S8 (monomer, approximate)
Research Protocols
intravenous Injection
- Tanezumab: 2.5-10 mg subcutaneous or intravenous, every 8 weeks.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Tanezumab | 2.5-10 mg, 2.5 mg, 5 mg | Per protocol | 8 weeks(Route: Subcutaneous Injection, Intravenous Injection) |
intranasal Injection
In animal models, intranasal NGF administration improves depressive-like behavior and hippocampal neurogenesis. - Intranasal rhNGF: Preclinical doses of 0.1-10 microg in rodent models.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Research Protocol | 2.5 mg, 5 mg | Per protocol | — |
topical
In the REPARO Phase II trial, topical rhNGF (20 microg/mL, 6 drops/day for 8 weeks) achieved corneal healing in 74.5% of patients with moderate-to-severe NK compared to 43.1% for vehicle (Bonini et al., 2018). Clinical Research Protocols - Cenegermin (Oxervate): 20 microg/mL topical ophthalmic solu
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Cenegermin (Oxervate) | See literature | Daily | 8 weeks(Route: Topical) |
intracerebroventricular Injection
Intracerebroventricular NGF delivery in early clinical trials caused back pain and weight loss, attributed to NGF effects on hypothalamic neurons. This necessitates direct CNS delivery methods such as gene therapy, intracerebroventricular infusion, encapsulated cell technology, or intranasal deliver
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Research Protocol | 2.5 mg, 5 mg | Per protocol | — |
subcutaneous Injection
- Tanezumab: 2.5-10 mg subcutaneous or intravenous, every 8 weeks. - Subcutaneous rhNGF: Phase II diabetic neuropathy trials used 0.1-0.3 microg/kg three times weekly (PMID: 10668695).
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Tanezumab | 2.5-10 mg, 2.5 mg, 5 mg | Per protocol | 8 weeks(Route: Subcutaneous Injection, Intravenous Injection) |
| Subcutaneous rhNGF | See literature | Once weekly | —(Route: Subcutaneous Injection) |
Interactions
Peptide Interactions
Cerebrolysin contains a mixture of neurotrophic peptides. Preclinical evidence suggests it may enhance endogenous NGF signaling in cholinergic pathways (Rockenstein et al., 2006).
NGF supports cholinergic neurons while BDNF supports hippocampal glutamatergic circuits. Co-administration may provide broader neuroprotection in AD models than either neurotrophin alone (Tuszynski et al., 2015).
What to Expect
What to Expect
Rapid onset expected; half-life of ~5 minutes (plasma); prolonged via depot formulations indicates fast-acting pharmacokinetics
In the REPARO Phase II trial, topical rhNGF (20 microg/mL, 6 drops/day for 8 weeks) achieved corneal healing in 74.
A subsequent Phase II trial using AAV2-NGF (CERE-110) delivered stereotactically to the nucleus basalis enrolled 49 patients but did not meet its...
Continued use as directed
Quality Indicators
What to look for
- Phase 3 clinical trial data available
- Well-established safety profile
- Extensive peer-reviewed research base
Frequently Asked Questions
References (26)
- [24]Pentz et al — The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimers disease Mol Psychiatry (2021)
- [10]Schnitzer TJ et al Subcutaneous tanezumab vs NSAID for treatment of osteoarthritis hip and knee pain JAMA (2019)
- [18]Salehi A et al Increased App expression in a mouse model of Down's syndrome disrupts NGF transport Neuron (2006)
- [3]
- [12]
- [26]Eftimiadi et al — Topical delivery of nerve growth factor for neurodegenerative diseases Pharmaceutics (2022)
- [1]
- [4]
- [5]
- [2]Kaplan DR & Miller FD Neurotrophin signal transduction in the nervous system Curr Opin Neurobiol (2000)
- [8]Castle MJ et al Postmortem analysis in a clinical trial of AAV2-NGF gene therapy for Alzheimer's disease Hum Gene Ther (2020)
- [6]Tuszynski MH et al A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease Nat Med (2005)
- [7]Rafii MS et al A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease Alzheimers Dement (2014)
- [9]Mufson EJ et al Cholinergic system during the progression of Alzheimer's disease J Chem Neuroanat (2008)
- [11]
- [13]Bonini S et al Topical recombinant nerve growth factor for neurotrophic keratitis (REPARO) Ophthalmology (2018)
- [14]Apfel SC et al Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy Neurology (2000)
- [16]Zweifel LS et al Functions and mechanisms of retrograde neurotrophin signalling Nat Rev Neurosci (2005)
- [19]Wahlberg LU et al Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease J Neurosurg (2012)
- [20]Simmons DA et al A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy J Neurosci (2014)
- [21]De Rosa R et al Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice Proc Natl Acad Sci USA (2005)
- [22]
- [25]Rocco et al — Nerve Growth Factor: Early Studies and Recent Clinical Trials Curr Neuropharmacol (2022)
- [15]Fahnestock M et al The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease Mol Cell Neurosci (2001)
- [17]Chuang HH et al Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition Nature (2001)
- [23]Cattaneo & Bhatt — Painless NGF for therapy Pharmacol Res (2024)
Neurotensin (NT)
Neurotensin is a 13-amino acid neuropeptide with endogenous antipsychotic-like properties, mediating hypothermia, antinociception, and dopamine modulation through NTS1 and NTS2 receptors. It is investigated as a basis for novel antipsychotic agents targeting schizophrenia without extrapyramidal side effects.
Nociceptin/Orphanin FQ
Nociceptin (Orphanin FQ, N/OFQ) is a 17-amino-acid neuropeptide that signals through the NOP receptor (ORL-1). Structurally related to dynorphin but functionally distinct from classical opioids, it modulates pain, stress, anxiety, and addiction through complex, often anti-opioid mechanisms.